EVEmily Mayerli Valencia-Mejía

Emily Mayerli Valencia-Mejía

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily Mayerli Valencia-Mejía has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Abordaje terapéutico y esquemas de tratamiento empleados en COVID-19 con angina de pecho

    by Emily Mayerli Valencia-Mejía, María Ilusión Solís-Sánchez, Kerly Katalina Llerena-Meza

    The impact of SARS-CoV-2 transcended the respiratory landscape and significantly compromised cardiovascular function, generating inflammation, endothelial alterations, and thrombotic disorders that favored the onset or worsening of angina pectoris. Given this clinical reality, a cross-sectional and explanatory literature review was conducted to describe the therapeutic algorithms applied in patients with a simultaneous diagnosis of COVID-19 and angina pectoris. The analysis of the literature identified the need for individualized and carefully supervised approaches. It was observed that the antiviral drug Remdesivir displayed an adequate safety profile in this group of patients, while the indiscriminate use of corticosteroids could generate adverse effects, particularly at the renal level. Furthermore, it was found that anticoagulant and antiplatelet drugs were essential for preventing thrombotic events, although their administration required constant medical monitoring. The results showed that coordination between specialists in cardiology, infectious disease, and intensive care increased the effectiveness of therapeutic interventions. Consequently, it was concluded that the treatment of patients with COVID-19 and angina should be guided by a multidisciplinary and dynamic approach, prioritizing cardiovascular stability without compromising control of the viral infection. The findings highlighted the importance of optimizing drug selection and establishing flexible protocols that respond to individual clinical conditions, thus forming a basis for future integrated therapeutic guidelines.